AI platform detects new drug targets in minutes
Fauna Bio has launched Fauna Brain™, a powerful new AI platform that leverages the company’s expertise in comparative genomics to accelerate drug target discovery.
List view / Grid view
Fauna Bio has launched Fauna Brain™, a powerful new AI platform that leverages the company’s expertise in comparative genomics to accelerate drug target discovery.
How do new cancer drugs make it to patients? This episode uncovers the challenges, successes, and AI advancements driving oncology treatments from preclinical screening to clinical trials.
DenovAI has unveiled a powerful AI-driven protein design platform capable of creating new, functional synthetic proteins from scratch - marking a big step forward for drug discovery.
James Atwood, COO of Opentrons, shares how accessible lab automation is helping research teams tackle tighter budgets, faster timelines and complex discovery workflows.
Genomics laid the foundation for precision medicine, but on its own, it offers only part of the picture. This article explores how integrated multiomics can provide the deeper biological context needed to drive more effective therapies forwards.
Lab scientists and data scientists often speak different languages and that miscommunication can slow down important research. In this interview, Ian Kerman shares how his team is working to break down those walls and spark better collaboration.
Drug development has long been hindered by fragmented data and complex processes, but a new wave of AI is reshaping the landscape. By integrating genomic, clinical and molecular data, multimodal models are revealing hidden patterns and accelerating more precise advancements in medicine.
Alltrna is redefining the future of rare disease treatment with engineered tRNA therapeutics that target genetic mutations - not just individual diseases. CEO Michelle Werner shares how this bold, mutation-driven approach could unlock universal treatments for thousands of patients long overlooked by traditional medicine.
Scientists have used AI to design a molecule that disrupts a key protein interaction driving up to 70 percent of cancers - once thought impossible to drug.
Generative AI is broadening the boundaries of what is possible in drug discovery. In this article, Murat Tunaboylu, CEO and Co-founder of Antiverse, reveals how the zeitgeist technology is enabling scientists to tackle previously undruggable targets like GPCRs and ion channels to deliver patient impact faster.
Forget the buzzwords - SLAS 2025 showed what’s genuinely driving progress in drug discovery: usable AI, collaborative platforms and tools that solve real problems.
Chief Scientific Officer at Solvias reveals how CROs are overcoming manufacturing challenges and harnessing AI to fast-track the development of groundbreaking cell and gene therapies.
As AI reshapes scientific work, two founders debate how best to build tools scientists can trust — should we embed expertise into the model or the team? From agent-powered labs to hypothesis-generating machines, the future of drug discovery is being reimagined right now.
The body undergoes changes with age that can lead to conditions like sarcopenia and osteoarthritis, burdening individuals and healthcare systems. Find out how Rejuvenate Biomed uses AI to decode ageing biology and develop combination therapies targeting the root causes of age-related diseases, offering hope for better treatments and quality of…
K Navigator, a new AI-powered research co-pilot, is set to transform biomedical science by helping researchers explore complex data and accelerate discoveries.